Further controversy was stirred during a Senate hearing in Australia, where Pfizer Australia’s top officials were questioned about their special employee vaccination program. Under intense scrutiny from Australian Senator Malcolm Roberts, Pfizer’s representatives confirmed the importation of a specific batch of COVID-19 vaccines intended solely for employee use, ensuring it would not draw from public vaccine supplies.
Senator Roberts pushed for clarity on the matter, particularly inquiring about the lack of testing by the Therapeutic Goods Administration (TGA) for the batch used for Pfizer employees, which led to a heated exchange about transparency and the ethics of internal vaccine distribution.
ALERT! Major Water Restrictions In Effect!
This revelation from a Pfizer whistleblower puts a spotlight on the pharmaceutical giant’s handling of vaccine distribution among its employees, raising ethical and potential legal questions about whether Pfizer employees were given preferential treatment or a different vaccine formulation from what was provided to the general public. As this story unfolds, it continues to provoke debate over corporate practices during the global pandemic and the implications for public trust in COVID-19 vaccination programs.
